Pharmaxis Group’s Post

"Had an incredible experience at CPHI 2024! It was amazing to connect with industry leaders, discover the latest innovations, and exchange insights that will shape the future of pharma. Here’s a glimpse of the key moments from the event! #CPHI2024 #PharmaInnovation #Networking #IndustryInsights #HealthcareFuture #CPHIExperience"

Looking forward to #World Drug Safety Congress Americas in October - Arietta.ai will be showing the latest in Applied AI for #pharmacovigilance

Pharmly is thrilled to announce that we’ll be exhibiting at CPHI 2024! You can find us at the Startup Section, stand 6SU6. Come by and discover how our AI-powered tool is revolutionizing the way final drug manufacturers find API and Excipient suppliers. We're thrilled to chat about how Pharmly can streamline your supply chain and offer quick demos to show you the future of sourcing in pharma. Don’t miss out—let’s connect and explore how we can support your business! #CPHI #Milan #PharmaInnovation #AIinPharma #Pharmly #SupplyChainExcellence #PharmaProcurement #APIProcurement #ExcipientProcurement

🌍 Announcing our new white paper: 𝗡𝗮𝘃𝗶𝗴𝗮𝘁𝗶𝗻𝗴 𝘁𝗵𝗲 𝗙𝘂𝘁𝘂𝗿𝗲: 𝗖𝗗𝗠𝗢 𝟮𝟬𝟮𝟱 𝗮𝗻𝗱 𝗕𝗲𝘆𝗼𝗻𝗱 The CDMO sector is rapidly evolving, driven by innovations in drug development, increased regulatory pressures, and the demand for faster, more flexible solutions. But what does the future hold for CDMOs, and how can organizations adapt to stay ahead? After a resounding success sending our latest industry briefing to our C-Suite priority group, we are opening this white paper up to others: an in-depth analysis based on meetings with leading industry consultants, analysts, and insights. This paper explores: 📊 Emerging trends shaping the CDMO landscape 🔍 Key challenges and opportunities for CDMOs in 2024 and beyond 💡 Implications for organisations growing in a dynamic market If you're involved in the biopharma or CDMO sectors as an executive you will find this extremely useful m, this is a must-read to stay informed and strategically aligned. 👉 Download the full white paper here https://lnkd.in/e9qXZ7B8 #CDMO #CPhI #CEO #COO #PharmaIndustry #Biopharma #DrugDevelopment #WhitePaper #IndustryInsights #PharmaInsights

At Vector Talent we know how important it is to stay on top of everything going on in the world of CDMO but it can been a challenge getting in front of the right people and getting into the right events. Don’t worry, we’ve got you covered with our latest CDMO briefing report. Check out the link below to access the latest insights from conversations with analysts, leaders and experts.

The countdown has begun!!! In just over two weeks, CPhI Worldwide will open its doors in Milan, and we will be there as always! We are excited to announce Navin Molecular's participation at the show. As a leading CDMO, we’re eager to showcase our cutting-edge solutions and discuss how we can help bring your innovations into the clinic. If you want to learn more about the technologies and capabilities we have in small molecules, which cover the entire product life cycle from development through to cGMP commercial manufacturing, please stop by our stand (7F14) where you can meet with the commercial team and our CEO, Rajendra Kumar Sahu, and discover how we can accelerate your project from concept to commercial production! Let's partner to drive innovation in the industry and grow together! Jordi Robinson, Ajay K. Ohri, Irfan Khan, Jay Ezhuthachan, Sagar Gawade, Jorg Gitzel, Matthew Stent #CPHI2024 #CPHIMilan #CDMO #Businessdevelopment #growth #ChemicalManufacturing #Innovation #Sustainability #IndustrialExcellence #Pharma #Chemical #Contractmanufacturing #opportunity #CRAMS #manufacturing #Customsynthesis #processdevelopment #Clinicalphasemanufacturing #supportforfilling #development #NCE #intermediates #processvalidation #regulatoryfilling #analyticaldevelopment #flowchemistry #peptides #processengineering #processsafety #intellectualproperty #Inlicensing #drugdiscovery #flourinechemistry #Phase I #Phase II #Phase III #Launched

Check out the report below to read more on the #CDMO outlook in 2024 along with a myriad of other pharma trends from our friends CPhI Conferences and Informa Markets

🚀 Last Thursday, I had the opportunity to present at the SAVE DATA event in Antwerp, where I discussed “Go-to-market strategies for Digital Therapeutics (DTx)”. Interested to learn more? Contact Nathalie Niclaus or myself at LIVV company. In the ever-evolving field of DTx, creating a commercially viable business requires navigating various commercialization pathways, from direct-to-consumer (D2C) approaches to partnerships with pharmaceutical companies and employer channels. During the session, we also explored reimbursement pathways in the EU, such as Germany’s DiGa and France’s PECAN, providing a roadmap for DTx companies aiming to achieve market penetration and scalability. 🌍 A big thank you to the organizers, all the attendees and fellow speakers for an insightful afternoon. Together, we’re paving the way for the future of digital health. Melanie Verstraete Roel Naessens Jeroen Crappé Ludovic Ampe Bieke Van Gorp MEDVIA imec #DigitalHealth #DigitalTherapeutics #GoToMarket #HealthTech #DiGa #PECAN #marketaccess #BusinessModels #HealthInnovation

For #biotech and #pharma companies seeking a competitive advantage, embracing a mindset focused on the #patientexperience is becoming a strategic imperative. Learn about four patient-centric trends shaping today’s #biopharma landscape, as detailed in the CPHI trend report, “The nexus between #patient and #bigpharma.” Additionally, explore how third-party vendors like integrated #CROs and #CDMOs can support #drugdevelopers in their efforts to prioritize patient centricity. Learn more here: http://spr.ly/604594ME3

As the sun sets at JFK International Air Terminal the Virtual Pharma Alliance S.R.L. Reflects on key takeaways from our interactions in the USA this past week… 1. The appetite for deals is as strong as ever, however after the “Biotech bubble” the need for data and details on products and technologies as part of the diligence process is greater than ever 2. Bolt on Vs Diversification - grow the core or branch out? Trends are emerging in subsectors particularly with Pharmaceutical companies and CRDMO’s… 3. Alliances Vs Acquisition - as the VPA has outlined in previous posts this trend to add value without fully absorbing complementary assets is surging, also there are very few total service providers in Pharma and alliances are going to be even more strategic in product development (develop and go - avoid integration dilution, avoid mega commitments to 3rd parties…) We thank all our current and potential customers and alliance partners for their time and look forward to continuing the evolution at CPHI in Milan and beyond! #pharmalution #evolution #strategy #development #r&d Virtual Pharma Alliance S.R.L. #formulation #api #excipient #medicaldevices #packaging #portfolio #usa #growth #new #future #cphi #businessdevelopment